

# William J Ellis

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/10511750/william-j-ellis-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

2,688  
citations

28  
h-index

51  
g-index

59  
ext. papers

3,003  
ext. citations

4.1  
avg. IF

4.25  
L-index

#	Paper	IF	Citations
54	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 418-426	4.2	3
53	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. <i>Urology Practice</i> , <b>2021</b> , 8, 576-582	0.8	
52	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , <b>2021</b> ,	6.4	1
51	Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 635-643	4	8
50	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. <i>Journal of Urology</i> , <b>2020</b> , 204, 701-706	2.5	9
49	The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 144-150	6.2	3
48	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 923-931 <sup>2,2</sup>		42
47	Continued 5 $\alpha$ Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. <i>Journal of Urology</i> , <b>2019</b> , 201, 106-111 <sup>2.5</sup>		3
46	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>European Urology</i> , <b>2018</b> , 73, 706-712	10.2	11
45	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. <i>Journal of Urology</i> , <b>2017</b> , 197, 1026-1033	2.5	10
44	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , <b>2017</b> , 72, 448-454	10.2	49
43	Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates. <i>Anti-Cancer Drugs</i> , <b>2017</b> , 28, 120-126	2.4	9
42	Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins. <i>Oncotarget</i> , <b>2017</b> , 8, 101887-101898	3.3	7
41	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. <i>Journal of Urology</i> , <b>2016</b> , 195, 313-20	2.5	93
40	Extreme Gleason Upgrading From Biopsy to Radical Prostatectomy: A Population-based Analysis. <i>Urology</i> , <b>2016</b> , 96, 148-155	1.6	10
39	Preliminary Comparative Effectiveness of Robotic Versus Open Radical Cystectomy in Elderly Patients. <i>Journal of Endourology</i> , <b>2016</b> , 30, 212-7	2.7	24
38	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. <i>European Urology</i> , <b>2015</b> , 68, 1083-8 <sup>10.2</sup>		39

37	Processing of voided urine for prostate cancer RNA biomarker analysis. <i>Prostate</i> , <b>2015</b> , 75, 1886-95	4.2	8
36	Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 333-8	6.7	18
35	The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1012-21	2.8	74
34	Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices. <i>Advances in Urology</i> , <b>2013</b> , 2013, 471234	1.6	1
33	A multiplex assay to measure RNA transcripts of prostate cancer in urine. <i>PLoS ONE</i> , <b>2012</b> , 7, e45656	3.7	9
32	Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine. <i>Prostate</i> , <b>2012</b> , 72, 1023-34	4.2	42
31	CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. <i>Modern Pathology</i> , <b>2010</b> , 23, 1346-56	9.8	79
30	Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. <i>Journal of Urology</i> , <b>2010</b> , 183, 2213-8	2.5	156
29	Development and evaluation of the personal patient profile-prostate (P3P), a Web-based decision support system for men newly diagnosed with localized prostate cancer. <i>Journal of Medical Internet Research</i> , <b>2010</b> , 12, e67	7.6	36
28	Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 677-83	12.9	181
27	"It's not like I can change my mind later": reversibility and decision timing in prostate cancer treatment decision-making. <i>Patient Education and Counseling</i> , <b>2009</b> , 77, 302-7	3.1	7
26	PCA3: a molecular urine assay for predicting prostate biopsy outcome. <i>Journal of Urology</i> , <b>2008</b> , 179, 1587-92	2.5	350
25	Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. <i>Cancer Research</i> , <b>2008</b> , 68, 5599-608	10.1	47
24	Point: open radical prostatectomy should not be abandoned. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2007</b> , 5, 685-8	7.3	11
23	PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. <i>Urology</i> , <b>2007</b> , 69, 532-5	1.6	348
22	The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2007</b> , 25, 214-20	2.8	33
21	Factors that predict treatment choice and satisfaction with the decision in men with localized prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2006</b> , 5, 219-26	3.3	47
20	Improved prostate cancer detection with anterior apical prostate biopsies. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 492-5	2.8	67

19	Telomerase activity in disseminated prostate cancer cells. <i>BJU International</i> , <b>2006</b> , 97, 1309-13	5.6	35
18	Qualitative Research Techniques <b>2006</b> , 297-310		0
17	Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 1306-11	12.9	31
16	Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. <i>Urology</i> , <b>2003</b> , 61, 277-81	1.6	100
15	Treatment decision-making by men with localized prostate cancer: the influence of personal factors. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2003</b> , 21, 93-100	2.8	95
14	Detection, Isolation and Study of Disseminated Prostate Cancer Cells in the Peripheral Blood and Bone Marrow. <i>Cancer Metastasis - Biology and Treatment</i> , <b>2003</b> , 87-116		
13	Detection, Isolation and Study of Disseminated Prostate Cancer Cells in the Peripheral Blood and Bone Marrow <b>2003</b> , 87-116		1
12	Prostate brachytherapy. <i>Cancer and Metastasis Reviews</i> , <b>2002</b> , 21, 125-9	9.6	6
11	Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. <i>Prostate</i> , <b>2001</b> , 47, 222-9	4.2	50
10	Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model. <i>Prostate</i> , <b>2000</b> , 43, 63-70	4.2	15
9	Analysis and sorting of prostate cancer cell types by flow cytometry. <i>Prostate</i> , <b>1999</b> , 40, 192-9	4.2	38
8	THE RELATIONSHIP BETWEEN SERIAL MEASUREMENTS OF THE LEVEL OF A BLADDER TUMOR ASSOCIATED ANTIGEN AND THE POTENTIAL FOR RECURRENCE. <i>Journal of Urology</i> , <b>1999</b> , 161, 57-61	2.5	18
7	THE VALUE OF A REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION ASSAY IN PREOPERATIVE STAGING AND FOLLOWUP OF PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , <b>1998</b> , 159, 1134-1138	2.5	62
6	Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. <i>Urology</i> , <b>1997</b> , 50, 573-9	1.6	49
5	Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. <i>Urology</i> , <b>1997</b> , 50, 184-8	1.6	55
4	Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. <i>Urology</i> , <b>1997</b> , 50, 882-7	1.6	114
3	Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. <i>International Journal of Cancer</i> , <b>1996</b> , 67, 785-90	7.5	47
2	Chemoprevention for prostate cancer. <i>Cancer</i> , <b>1995</b> , 75, 1783-1789	6.4	11

- 1      Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. *Journal of Urology*, **1994**, 152, 1520-5      2.5      115